
    
      This open-label, uncontrolled, extension study is designed to assess the long-term safety of
      carvedilol in pediatric patients with heart failure and includes the following phases:

        1. Screening Phase (coincides with the final maintenance Month 6 Visit in the 321 study

        2. Down-/Up-titration Phase

        3. Maintenance Phase

        4. Down-titration

        5. Follow-up
    
  